LifeStance Health Group (NASDAQ:LFST) PT Lowered to $7.50

LifeStance Health Group (NASDAQ:LFST) had its price target reduced by UBS Group from $9.00 to $7.50 in a research report released on Thursday, Benzinga reports. They currently have a neutral rating on the stock.

Several other analysts also recently weighed in on the company. Barclays decreased their target price on LifeStance Health Group from $8.00 to $6.00 and set an underweight rating for the company in a research report on Friday, August 9th. Morgan Stanley reiterated an overweight rating and set a $10.00 price objective on shares of LifeStance Health Group in a report on Monday, April 22nd. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Hold and an average target price of $8.25.

LifeStance Health Group Trading Down 3.3 %

Shares of LFST opened at $5.65 on Thursday. LifeStance Health Group has a twelve month low of $4.64 and a twelve month high of $9.20. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.20. The company’s fifty day simple moving average is $5.39 and its 200-day simple moving average is $6.06. The company has a market cap of $2.16 billion, a P/E ratio of -11.77 and a beta of 1.20.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Thursday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. LifeStance Health Group had a negative return on equity of 11.92% and a negative net margin of 15.69%. The business had revenue of $312.30 million during the quarter, compared to analyst estimates of $305.85 million. During the same quarter in the previous year, the business earned ($0.13) earnings per share. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. As a group, analysts expect that LifeStance Health Group will post -0.25 EPS for the current year.

Insider Activity

In related news, major shareholder Summit Partners Growth Equity sold 3,802,345 shares of the company’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $5.89, for a total value of $22,395,812.05. Following the completion of the sale, the insider now directly owns 41,932,358 shares of the company’s stock, valued at $246,981,588.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other LifeStance Health Group news, insider Kevin Michael Mullins sold 85,093 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $5.53, for a total value of $470,564.29. Following the completion of the transaction, the insider now directly owns 4,650,571 shares in the company, valued at $25,717,657.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Summit Partners Growth Equity sold 3,802,345 shares of the stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $5.89, for a total transaction of $22,395,812.05. Following the sale, the insider now directly owns 41,932,358 shares of the company’s stock, valued at $246,981,588.62. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,037,438 shares of company stock worth $23,647,876. Company insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LFST. Charles Schwab Investment Management Inc. grew its holdings in LifeStance Health Group by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 744,617 shares of the company’s stock worth $5,830,000 after purchasing an additional 5,112 shares during the last quarter. Swiss National Bank increased its position in LifeStance Health Group by 25.4% during the 1st quarter. Swiss National Bank now owns 186,800 shares of the company’s stock valued at $1,153,000 after buying an additional 37,800 shares in the last quarter. Brown Advisory Inc. increased its position in LifeStance Health Group by 25.9% during the 4th quarter. Brown Advisory Inc. now owns 5,158,980 shares of the company’s stock valued at $40,395,000 after buying an additional 1,062,887 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in LifeStance Health Group by 2.8% in the fourth quarter. Principal Financial Group Inc. now owns 4,006,344 shares of the company’s stock worth $31,370,000 after acquiring an additional 110,457 shares in the last quarter. Finally, Assetmark Inc. grew its stake in shares of LifeStance Health Group by 21.6% during the fourth quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock worth $93,000 after acquiring an additional 2,114 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.